The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom
Abstract
The age-adjusted incidence of new factor VIII inhibitors was analyzed in all United Kingdom patients with severe hemophilia A between 1990 and 2009. Three hundred fifteen new inhibitors were reported to the National Hemophilia Database in 2528 patients with severe hemophilia who were followed up for a median (interquartile range) of 12 (4-19) years. One hundred sixty (51%) of these arose in patients ≥ 5 years of age after a median (interquartile range) of 6 (4-11) years' follow-up. The incidence of new inhibitors was 64.29 per 1000 treatment-years in patients < 5 years of age and 5.31 per 1000 treatment-years at age 10-49 years, rising significantly (P = .01) to 10.49 per 1000 treatment-years in patients more than 60 years of age. Factor VIII inhibitors arise in patients with hemophilia A throughout life with a bimodal risk, being greatest in early childhood and in old age. HIV was associated with significantly fewer new inhibitors. The inhibitor incidence rate ratio in HIV-seropositive patients was 0.32 times that observed in HIV-seronegative patients (P < .001). Further study is required to explore the natural history of later-onset factor VIII inhibitors and to investigate other potential risk factors for inhibitor development in previously treated patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Darby, S. C., Kan, S. W., Spooner, R. J., Giangrande, P. L. F., Hill, F. G. H., Hay, C. R. M., Lee, C. A., Ludlam, C. A., & Williams, M. (2007) · Blood · doi:10.1182/blood-2006-10-050435 · Cited by 511
Self-citationGouw, S. C., van der Bom, J. G., & Marijke van den Berg, H. (2007) · Blood · doi:10.1182/blood-2006-11-056291 · Cited by 495
Factor VIII Inhibitors in Mild and Moderate-severity Haemophilia A
Ludlam, C. A., Colvin, B. T., Hill, F. G. H., Preston, F. E., Wasseem, N., Bagnall, R., Peake, I. R., Berntorp, E., Bunschoten, E. P. M., Fijnvandraat, K., et al. (1998) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615061 · Cited by 187
Self-citationHay, C. R. M., Ludlam, C. A., Colvin, B. T., Hill, F. G. H., Preston, F. E., Wasseem, N., Bagnall, R. D., Peake, I. R., Berntorp, E. E., Mauser‐Bunschoten, E. P., et al. (1998) · PubMed · Cited by 186
Self-citationMcMillan, C., Shapiro, S., Whitehurst, D., Hoyer, L., Rao, A., & Lazerson, J. (1988) · Blood · doi:10.1182/blood.v71.2.344.344 · Cited by 169
Prevalence of Inhibitors in a Population of 3435 Hemophilia Patients in France
Sultan, Y., & French Hemophilia Study Group (1992) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1648507 · Cited by 135
White, G. C., Courter, S. G., Bray, G. L., Lee, M., & Gomperts, E. D. (1997) · PubMed · Cited by 123
White, G. C., Courter, S. G., Bray, G. L., Lee, M., Gomperts, E. D., & The Recombinate Previously Treated Patient Study Group (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1656030 · Cited by 116
The Multifactorial Etiology of Inhibitor Development in Hemophilia: Genetics and Environment
Gouw, S. C., & van den Berg, H. M. (2009) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0029-1245105 · Cited by 105
Basic aspects of inhibitors to factors VIII and IX and the influence of non‐genetic risk factors
Astermark, J. (2006) · Haemophilia · doi:10.1111/j.1365-2516.2006.01360.x · Cited by 100
Cited by
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Factor VIII Products and Inhibitor Development in Severe Hemophilia A
Gouw, S. C., van der Bom, J. G., Ljung, R., Escuriola, C., Cid, A. R., Claeyssens-Donadel, S., van Geet, C., Kenet, G., Mäkipernaa, A., Molinari, A. C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208024 · Cited by 440
Gouw, S. C., van den Berg, H. M., Oldenburg, J., Astermark, J., de Groot, P. G., Margaglione, M., Thompson, A. R., van Heerde, W., Boekhorst, J., Miller, C. H., et al. (2012) · Blood · doi:10.1182/blood-2011-09-379453 · Cited by 358
Factor VIII inhibitors in hemophilia A: rationale and latest evidence
Witmer, C., & Young, G. (2013) · Therapeutic Advances in Hematology · doi:10.1177/2040620712464509 · Cited by 231
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A
Eckhardt, C. L., van Velzen, A. S., Peters, M., Astermark, J., Brons, P. P., Castaman, G., Cnossen, M. H., Dors, N., Escuriola-Ettingshausen, C., Hamulyak, K., et al. (2013) · Blood · doi:10.1182/blood-2013-02-483263 · Cited by 220
Self-citation
Metadata
- Authors
- Hay, C. R. M., Palmer, B., Chalmers, E., Liesner, R., Maclean, R., Rangarajan, S., Williams, M., Collins, P. W., & on behalf of United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO)
- Affiliations
- Manchester Royal Infirmary (GB)
- The United Kingdom National Haemophilia Database, Manchester, United Kingdom;
- Department of Haematology, Glasgow Hospital for Sick Children, Yorkhill, Glasgow, United Kingdom;
- Great Ormond Street Hospital (GB)
- Royal Hallamshire Hospital (GB)
- St Thomas' Hospital (GB)
- Birmingham Children's Hospital (GB)
- University Hospital of Wales (GB)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2011-06-09
- Volume
- 117
- Issue
- 23
- Pages
- 6367-6370
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2100236686
- Cited by
- 174
- References
- 17
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 4 · 2023: 5 · 2022: 8 · 2021: 11 · 2020: 15 · 2019: 5 · 2018: 19 · 2017: 17 · 2016: 13 · 2015: 17 · 2014: 16 · 2013: 15 · 2012: 19
- FWCI
- 11.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- factor VIII inhibitors, hemophilia A, inhibitor incidence, age-related risk, HIV infection, risk factors
- MeSH terms
- Adolescent, Adult, Age Factors, Child, Child, Preschool, Factor VIII, Female, United Kingdom, Hemophilia A, HIV Seropositivity, Humans, Male, Retrospective Studies, Risk Factors, Incidence, Databases, Factual, Blood Coagulation Factor Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. https://app.cochat.ai/papers/10.1182/blood-2010-09-308668
- The paper
- Hay, C. R. M., Palmer, B., Chalmers, E., Liesner, R., Maclean, R., Rangarajan, S., Williams, M., Collins, P. W., & on behalf of United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO). (2011). Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood. https://doi.org/10.1182/blood-2010-09-308668
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.